Wilson Jack, Langcake Andrew, Bryant Zachary, Freeman Tom P, Leung Janni, Chan Gary C K, Englund Amir, Graham Myfanwy, Stockings Emily
The Matilda Centre for Research in Mental Health and Substance Use, Level 6 Jane Foss Russell Building, The University of Sydney, Camperdown, NSW, 2006, Australia.
Addiction and Mental Health Group (AIM), University of Bath, Bath, BA2 7AY, UK.
Syst Rev. 2025 Jan 24;14(1):23. doi: 10.1186/s13643-024-02657-3.
There has been a global increase in the use of cannabinoids as a treatment for mental health (MH) and substance use disorders (SUD). In 2016, an Australian government-funded review found that although medicinal cannabinoids accounted for a small reduction in MH symptoms, the results varied according to study design. There has since been a rise in randomised controlled trials (RCTs) aiming to examine the efficacy of cannabinoids for the treatment of MH and SUD. Therefore, the current systematic review will (a) identify all RCTs examining the efficacy of cannabinoids in treating MH and SUD, (b) provide a quantitative or narrative synthesis of the evidence examining efficacy, and (c) synthesise adverse event data to examine evidence of harm. Electronic databases (Ovid MEDLINE, PsychINFO, Cochrane Central Register of Controlled Clinical Trials, Cochrane Database of Systematic Reviews, and Embase) were searched from 1980 to 24 May 2023. The study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Guidelines. Articles will be screened to capture peer-reviewed RCTs evaluating the efficacy of plant-based and pharmaceutical cannabinoids in reducing or treating MH and SUD among people of any age. The Cochrane risk of bias tool 2.0 will be used to assess bias, while the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) tool will be used to assess the quality of evidence for each outcome. Study findings will be disseminated through published manuscripts, conferences, and health policy guidelines.Systematic review registration PROSPERO CRD42023392718.
全球范围内，大麻素用于治疗心理健康（MH）和物质使用障碍（SUD）的情况有所增加。2016年，一项由澳大利亚政府资助的综述发现，尽管药用大麻素能使MH症状略有减轻，但结果因研究设计而异。此后，旨在研究大麻素治疗MH和SUD疗效的随机对照试验（RCT）有所增加。因此，本次系统综述将（a）确定所有检验大麻素治疗MH和SUD疗效的RCT，（b）对检验疗效的证据进行定量或叙述性综合分析，以及（c）综合不良事件数据以检验危害证据。检索了1980年至2023年5月24日的电子数据库（Ovid MEDLINE、PsychINFO、Cochrane临床对照试验中心注册库、Cochrane系统评价数据库和Embase）。本研究遵循系统评价和Meta分析的首选报告项目指南。将筛选文章，以获取评估植物性和药用大麻素在减轻或治疗任何年龄人群的MH和SUD方面疗效的同行评审RCT。将使用Cochrane偏倚风险工具2.0评估偏倚，同时使用推荐分级、评估、制定和评价（GRADE）工具评估每个结果的证据质量。研究结果将通过发表的手稿、会议和卫生政策指南进行传播。系统评价注册PROSPERO CRD42023392718。
